A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST) Meeting Abstract
| Authors: | Somaiah, N.; Van Tine, B. A.; Chmielowski, B.; Drabick, J. J.; Chawla, S. P.; McKean, M.; Spira, A. I.; O'Byrne, K. J.; Foresto, S. A.; Movva, S.; Kim, A.; Gastman, B.; Pressey, J. G.; Paudyal, B.; De, A.; Winkler, R. E.; Li, M.; Ahmad, M.; Yang, D.; Zhai, Y. |
| Abstract Title: | A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.e14627 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: e14627 -- Meeting also presented virtually -- Source: Cinahl |
